An article discusses the multifactorial nature of obesity, highlighting its association with chronic low-grade inflammation, or meta-inflammation, which contributes to metabolic disorders. Pyruvate was found to inhibit adipogenic differentiation in vitro and significantly prevent HFD-induced weight gain and inflammation in mice. The study underscores pyruvate's potential as a therapeutic option for obesity, given its previous clinical use and safety. Key findings from the study include: Pyruvate reduced intracellular lipid and triglyceride accumulation, indicating its effectiveness in suppressing adipogenesis across different cell types. In vivo experiments with male mice indicated that pyruvate administration significantly prevented HFD-induced weight gain and central adiposity....
